See more : Impero A/S (IMPERO.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Pila Pharma AB (publ) (PILA.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pila Pharma AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Landcadia Holdings III, Inc (LCY) Income Statement Analysis – Financial Results
- M.W. Trade SA (MWT.WA) Income Statement Analysis – Financial Results
- SIG plc (SHI.L) Income Statement Analysis – Financial Results
- Spectrum Foods Ltd. (SPECFOOD.BO) Income Statement Analysis – Financial Results
- Arogo Capital Acquisition Corp. (AOGOU) Income Statement Analysis – Financial Results
Pila Pharma AB (publ) (PILA.ST)
About Pila Pharma AB (publ)
PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 1.46M | 1.88M | 719.23K | 0.00 | 346.44K | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 10.77M | 38.29K | 492.39K | 2.43M | 2.93M | 7.53K | 379.88K | 660.56K |
Gross Profit | 1.46M | -8.89M | 680.94K | -492.39K | -2.08M | -2.93M | -7.53K | -379.88K | -660.56K |
Gross Profit Ratio | 100.00% | -472.64% | 94.68% | 0.00% | -600.96% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 5.07M | 1.51M | 1.48M | 785.43K | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 0.00 | 958.00 | 5.07M | 1.51M | 1.48M | 785.43K | 4.79M | 1.08M | 239.29K |
Other Expenses | 7.86M | 10.77M | 4.87M | 1.38M | 1.15M | 1.23M | 0.00 | 0.00 | 0.00 |
Operating Expenses | 7.86M | 10.77M | 9.94M | 2.89M | 2.64M | 2.02M | 4.79M | 1.09M | 239.29K |
Cost & Expenses | 7.86M | 10.77M | 9.98M | 3.38M | 5.06M | 4.95M | 4.79M | 1.47M | 899.85K |
Interest Income | 0.00 | 658.00 | 30.54K | 202.00 | 882.00 | 0.00 | 27.15K | 17.17K | 416.00 |
Interest Expense | 40.09K | 658.00 | 30.54K | 202.00 | 882.00 | 944.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 1.08M | 15.63K | 20.15K | 20.15K | 20.15K | 17.13K | 7.53K | 1.47M | 899.85K |
EBITDA | -8.81M | -26.76M | -17.16M | -3.36M | -8.65M | -4.93M | -4.73M | -17.17K | -416.00 |
EBITDA Ratio | -602.35% | -471.86% | -1,284.77% | 0.00% | -1,356.09% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -6.39M | -8.89M | -9.26M | -3.38M | -4.72M | -4.95M | -4.79M | -1.47M | -899.85K |
Operating Income Ratio | -436.99% | -472.69% | -1,287.57% | 0.00% | -1,361.90% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -3.54M | -17.89M | -7.95M | -3.60M | -3.95M | -650.94K | 26.60K | -17.17K | -416.00 |
Income Before Tax | -9.93M | -26.78M | -17.21M | -6.98M | -8.67M | -5.60M | -4.77M | -1.49M | -900.27K |
Income Before Tax Ratio | -678.73% | -1,423.74% | -2,392.46% | 0.00% | -2,502.34% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | 17.89M | 7.95M | 3.60M | 3.95M | -650.00K | -3.00 | -17.17K | -416.00 |
Net Income | -9.93M | -44.66M | -25.15M | -10.58M | -12.62M | -5.60M | -4.77M | -1.49M | -900.27K |
Net Income Ratio | -678.73% | -2,374.74% | -3,497.34% | 0.00% | -3,642.78% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -0.47 | -2.59 | -1.88 | -0.67 | -0.80 | -0.36 | -0.30 | -0.10 | -0.06 |
EPS Diluted | -0.47 | -2.59 | -1.88 | -0.67 | -0.80 | -0.36 | -0.30 | -0.10 | -0.06 |
Weighted Avg Shares Out | 21.10M | 17.25M | 13.40M | 15.71M | 15.71M | 15.71M | 15.71M | 15.71M | 15.71M |
Weighted Avg Shares Out (Dil) | 21.10M | 17.25M | 13.40M | 15.71M | 15.71M | 15.71M | 15.71M | 15.71M | 15.71M |
Source: https://incomestatements.info
Category: Stock Reports